Clinical Trial: Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07179939) titled 'Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study' on Aug. 06.

Brief Summary: This is a phase II trial exploring the maintenance therapy with trastuzumab combined with pyrotinib or dalpiciclib and endocrine therapy in HER2-positive advanced breast cancer based on different hormone receptor (HR) statuses following trastuzumab rezetecan (T-DXh, SHR-A1811) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC) patients.

Study Start Date: Sept. 10

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Inter...